Table 1. Overall and GFR stratified analysis for CIAKI prevention, with NNT.
| Treatment | Overall analysis | GFR 59–30 ml/min | GFR <30 ml/min | |||
|---|---|---|---|---|---|---|
| Probability to be the best [%] | NNT | Probability to be the best [%] | NNT | Probability to be the best [%] | NNT | |
| Saline | - | - | - | - | - | - |
| Saline plus N-acetylcysteine | 0.0 | 30.79 | 0.0 | 33.90 | 16.99 | 5.35 |
| Sodium bicarbonate | 0.0 | 32.61 | 0.0 | 35.74 | na | na |
| Sodium bicarbonate plus N-acetyl cysteine | 0.006 | 20.22 | 0.001 | 24.89 | na | na |
| Ascorbic acid | 0.03 | 19.97 | 0.004 | 25.63 | na | na |
| Statin | 1.53 | 13.07 | 1.14 | 14.57 | na | na |
| Furosemide | 0.0 | -14.29 | 0.13 | -5.35 | 0.73 | -3.51 |
| Probucol | 5.24 | 13.48 | na | na | na | na |
| Methylxanthines | 2.17 | 13.48 | 3.66 | 14.10 | na | na |
| Fenoldopam | 0.01 | 14.81 | 0.02 | -9.52 | 1.64 | -2.31 |
| Device-guided matched hydration | 12.45 | 12.15 | 11.74 | 11.62 | na | na |
| Renal replacement therapy | 0.14 | 19.74 | 0.002 | -5.61 | 62.40 | 4.72 |
| Nebivolol | 0.94 | 14.81 | 1.93 | 13.97 | na | na |
| Natriuretic peptides | 3.22 | 14.84 | 0.78 | -3.93 | 18.24 | 5.49 |
| Mannitol | 1.13 | 13.52 | 8.22 | 10.71 | na | na |
| Prostaglandins | 31.03 | 10.87 | 35.63 | 10.24 | na | na |
| Trimetazidine | 27.38 | 10.97 | 33.24 | 10.43 | na | na |
| LVEDP-guided hydration | 14.37 | 12.21 | 3.51 | 13.43 | na | na |
CIAKI = contrast-induced acute kidney injury. GFR = glomerular filtration rate; na = not available; NNT = number needed to treat to prevent one episode of CIAKI.